

Table 6  
Ongoing clinical trials for COVID-19 vaccines [212–239]

Vaccine	Company	Platform	Phase/Status	Primary purpose	Trial description	Location
BCG Vaccine [212]	Texas A&M University	Live attenuated	IV Recruiting	Prevention	A randomized, parallel assignment trial N = 1800, health care workers (HCW) Study start date: April 20, 2020	USA
BCG Vaccine [213]	Hellenic Institute for the Study of Sepsis	Live attenuated	IV Recruiting	Prevention	A randomized, parallel assignment trial N = 900 Study start date: May 26, 2020	Greece
BCG Vaccine [214]	Murdoch Children's Research Institute	Live attenuated	III Recruiting	Prevention	A randomized, parallel assignment trial N = 4170, HCW Study start date: March 30, 2020	Australia
BCG Vaccine [215]	UMC Utrecht	Live attenuated	III Recruiting	Prevention	A randomized, parallel assignment trial N = 1500, HCW Study start date: March 25, 2020	Netherlands
BCG Vaccine [216]	TASK Applied Science	Live attenuated	III Recruiting	Prevention	A randomized, parallel assignment trial N = 500, HCW Study start date: April 28, 2020	South Africa
VPM1002 [217]	Vakzine Projekt Management GmbH	Live attenuated	III Recruiting	Prevention	A randomized, parallel assignment trial N = 1200, HCW Study start date: May 25, 2020	Germany
VPM1002 [218]	Vakzine Projekt Management GmbH	Live attenuated	III Recruiting	Prevention	A randomized, parallel assignment trial N = 2038, people over 60 y/o Estimated study start date: June, 2020	Germany
MMR vaccine [219]	Kasr El Aini Hospital	Live attenuated	III Recruiting	Prevention	A randomized, parallel assignment trial N = 200, HCW Study start date: June 16, 2020	Turkey
ChAdOx1 nCoV-19 [220]	University of Oxford	Non-Replicating Viral Vector	II/III Recruiting	Prevention	A randomized, sequential assignment trial N = 10260 Study start date: May 28, 2020	UK
Ad5-nCoV [221]	Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China/CanSino Bio, Inc. ModernaTX, Inc.	Non-Replicating Viral Vector RNA	II Active, not recruiting II Recruiting	Prevention	A randomized, crossover assignment for evaluation of Ad5-nCoV, which encodes for full-length S-protein of SARS-CoV-2. N = 500 Study start date: April 12, 2020 A non-randomized, sequential assignment trial N = 600	China USA
Inactivated SARS-CoV-2 Vaccine [223]	Sinovac/Development Co., Ltd.	Inactivated	I/II Recruiting	Prevention	A randomized, parallel assignment trial for the prevention of the COVID-19 disease N = 744 Study start date: April 16, 2020	China

(Continued)